Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

iShares S&P 500 ETF

IVV

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

CSL Limited

CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.

Resolution Minerals Ltd

RML

Resolution Minerals Ltd. operates as a resource company, which engages in the acquisition, exploration, and development of cobalt mineral projects. The company is headquartered in Adelaide, South Australia. The company went IPO on 2017-09-22. Its Horse Heaven Antimony-Gold-Tungsten Project is well-situated in Valley County, Idaho United States. The Horse Heaven Project comprises 699 federal lode mining claims covering over 5,644 hectares. Its George Project covers a large area prospective for roll-front style uranium (2,839km2) in central South Australia. The Company’s Drake East Project hosts fourteen known antimony occurrences, including the well-documented Mosquito Creek Antimony-Gold Reef and Ball & Smiths Lode. These antimony occurrences cover a large area with a NW-SE strike length of over 15 kilometers (km). Its Neardie Project hosts three past producing antimony mines. Its Spur South Gold-Copper Project is located within the highly mineralized Macquarie Arc region in NSW.